McGowan Donna
Br J Nurs. 2015 Sep;24(16 Suppl 1):S14-20. doi: 10.12968/bjon.2015.24.sup16a.s14.
While monoclonal antibodies (MABs) are not as hazardous as cytotoxic drugs, there is concern among health professionals about the potential risks and the limited evidence about this. Guidance on the safe use of MABs is mainly to be found in national documents covering all systemic anti-cancer therapies, with the only consensus guidelines specifically on MABs coming from Australia. This article therefore summarises the existing guidance relating to MABs.
虽然单克隆抗体（MABs）不像细胞毒性药物那样危险，但卫生专业人员对其潜在风险以及相关证据有限表示担忧。关于单克隆抗体安全使用的指南主要见于涵盖所有全身抗癌疗法的国家文件，专门针对单克隆抗体的唯一共识指南来自澳大利亚。因此，本文总结了与单克隆抗体相关的现有指南。
